• Pifithrin-α for p53 Mechanism Studies

  2026-10-02

  Pifithrin-α (PFTα) is a practical p53 inhibitor for separating p53-driven transcriptional effects from downstream ferroptotic injury, apoptosis, and radiation responses. This guide converts a developmental neurotoxicity study into executable HT-22 workflows, controls, optimization strategies, and interpretation safeguards.

• S-Adenosylhomocysteine in Neural Methylation Assays

  2026-10-01

  S-Adenosylhomocysteine (SAH) enables controlled methyltransferase inhibition and SAM/SAH ratio modulation in cell-based experiments. This guide translates radiation-induced neural differentiation findings into practical SAH workflows, controls, and troubleshooting strategies without confusing a proposed metabolic perturbation with a mechanism established by the reference study.

• CD36 Lipid Signaling and Immune Escape in AML

  2026-10-01

  Guo et al. identify a non-canonical CD36 program in AML in which oxidized LDL and palmitate cooperate to activate innate immune signaling and suppress T-cell activity. The study also shows that lipid restriction with statins can improve decitabine efficacy, while highlighting why metabolic context matters when interpreting immunotherapy resistance.

• Bleomycin Sulfate: DNA Damage Meets Repair

  2026-09-30

  Bleomycin Sulfate, also known as Blenoxane, is more than a DNA-damaging reagent. This article explains how ATM-dependent repair state, assay timing, and fibrosis modeling can determine what its biological readouts actually mean.

• Nelfinavir Mesylate: Designing Orthogonal Assays

  2026-09-30

  Nelfinavir Mesylate is a potent HIV-1 protease inhibitor with applications extending from HIV replication suppression to mechanistic ferroptosis research. This guide presents an orthogonal assay strategy for separating antiviral activity, DDI2–NFE2L1 signaling, proteasome stress, and cell death.

• Recombinant Human FGF-19: Assay Reliability

  2026-09-29

  A scenario-driven guide to designing reproducible FGFR4 binding, proliferation, viability, and metabolic regulation experiments with Recombinant Human FGF-19 (E.coli, Tag Free, Lyophilized), SKU P1050. It covers receptor compatibility, reconstitution, activity controls, interpretation limits, and practical vendor-selection criteria.

• Phosbind Acrylamide: Reliable Phosphorylation Analysis

  2026-09-29

  This scenario-based guide explains how Phos binding reagent (Phosbind) acrylamide, SKU F4002, can connect cell-based phenotypes with antibody-independent protein phosphorylation analysis. It covers gel compatibility, protocol controls, interpretation, storage, and practical vendor-selection criteria.

• Osteoblast ECM1 Drives Anti-Androgen Resistance

  2026-09-28

  The reference study identifies osteoblast-derived ECM1 as a treatment-responsive driver of enzalutamide resistance in bone metastatic prostate cancer. Its mechanistic model links ECM1 to ENO1 phosphorylation, GRB2/SOS1 recruitment, and MAPK activation, while ECM1 inhibition or ENO1 targeting restores enzalutamide sensitivity.

• MK-571 Workflows for Inflammation and MRP1 Studies

  2026-09-28

  Use MK-571 (L-660,711) to probe cysteinyl-leukotriene signaling or, with appropriate controls, ABCC1/MRP1-associated drug handling. This guide turns those distinct activities into practical workflows while flagging the controls needed to separate receptor effects from transporter-related findings.

• ZNF263 Drives CRC Progression and CRT Resistance

  2026-09-27

  The study links elevated ZNF263 with colorectal cancer (CRC) severity and shows that ZNF263 can promote malignant cell behaviors through transcriptional regulation of STAT3. Its experiments connect this pathway to reduced sensitivity to chemoradiotherapy, suggesting a candidate mechanism for investigation—not yet a clinically validated biomarker or treatment target.

• ROS-Driven Metabolic Rewiring in BRAF-Inhibited Melanoma

  2026-09-26

  Cesi et al. report that inhibiting MAPK signaling in melanoma cells increases reactive oxygen species and activates pyruvate dehydrogenase kinases, which inhibit pyruvate dehydrogenase. Their findings identify PDK activity as a potential metabolic vulnerability, including in BRAF-inhibitor-resistant cells, while emphasizing that the evidence comes from cell models rather than clinical testing.

• MaMT4 Enables C/N-Selective Alkaloid Methylation

  2026-09-25

  A 2026 study identifies mulberry MaMT4 as a methyltransferase that can modify different piperidine substrates at either carbon or nitrogen positions, and links its activity to DNJ-type alkaloid accumulation in leaves. Kinetic, genetic, and mutational evidence points to substrate-dependent recognition involving residues F363 and I80, offering a framework for studying methylation selectivity in plant alkaloid biosynthesis.

• Estradiol Limits ER Stress After Hemorrhagic Shock

  2026-09-25

  In a rat hemorrhagic-shock model, estradiol was associated with recovery of splenic CD4+ T-cell proliferation and cytokine production alongside reduced endoplasmic reticulum stress. Pharmacological comparisons implicate ERα and GPR30, but not ERβ, and suggest that controlling stress responses may help preserve immune function after shock.

• BIBP 3226 in Adipose-Neural Arrhythmia Research

  2026-09-24

  Learn how BIBP 3226 trifluoroacetate can help test the NPY Y1R contribution to epicardial adipose tissue-related arrhythmia, with practical controls for separating receptor effects from broader neuropeptide signaling. The workflow connects the 2024 adipose-neural study to a cautious, dose-ranging antagonist strategy and includes troubleshooting for cell-based assays.

• Oleic Acid (C18:1(9Z)) in Lipid Research

  2026-09-24

  Oleic Acid (C18:1(9Z)) is a monounsaturated fatty acid used to perturb lipid handling and signaling in experimental models. A study of hepatic ischemia/reperfusion injury used oleic acid together with palmitic acid to create a lipid-loaded hepatocyte model, so its findings do not isolate the effect of oleic acid alone.

7386 records 2/493 page Previous Next 12345 下5页 Last page